OncoMatch/Clinical Trials/NCT05439278
Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
Is NCT05439278 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Temozolomide for glioblastoma.
Treatment: Temozolomide — In newly diagnosed glioblastoma patients aged 70 years or older who are suitable for concurrent temozolomide, the optimal dose of radiation therapy is controversial . The purpose of this study is to compare conventional radiotherapy of 60 Gy (6 weeks) versus hypofractionated radiotherapy of 40 Gy (3 weeks) in terms of overall survival as the primary endpoint along with progression-free survival, toxicity, quality of life, and prognostic biomarkers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: MGMT promoter methylation status known
known o6-methylguanine-DNA-methyltransferase promoter methylation status
Prior therapy
Cannot have received: brain radiotherapy
no history of brain radiotherapy
Cannot have received: systemic chemotherapy
no history of any systemic chemotherapy
Lab requirements
Blood counts
adequate hematological function for temozolomide
Kidney function
adequate renal function for temozolomide
Liver function
adequate hepatic function for temozolomide
adequate hematological, renal and hepatic functions for temozolomide
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify